These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17127264)

  • 1. Phytate acts as an inhibitor in formation of renal calculi.
    Grases F; Isern B; Sanchis P; Perello J; Torres JJ; Costa-Bauza A
    Front Biosci; 2007 Jan; 12():2580-7. PubMed ID: 17127264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary phytate in calcium oxalate stone formers and healthy people--dietary effects on phytate excretion.
    Grases F; March JG; Prieto RM; Simonet BM; Costa-Bauzá A; García-Raja A; Conte A
    Scand J Urol Nephrol; 2000 Jun; 34(3):162-4. PubMed ID: 10961468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytate prevents tissue calcifications in female rats.
    Grases F; Prieto RM; Simonet BM; March JG
    Biofactors; 2000; 11(3):171-7. PubMed ID: 10875304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates.
    Grases F; Ramis M; Costa-Bauzá A
    Urol Res; 2000 Apr; 28(2):136-40. PubMed ID: 10850638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.
    Grases F; Costa-Bauzá A
    Anticancer Res; 1999; 19(5A):3717-22. PubMed ID: 10625946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential thermodynamic and kinetic roles of phytate as an inhibitor of kidney stone formation: theoretical modelling and crystallization experiments.
    Fakier S; Rodgers A; Jackson G
    Urolithiasis; 2019 Dec; 47(6):493-502. PubMed ID: 30767040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
    Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development.
    Costa-Bauzá A; Isern B; Perelló J; Sanchis P; Grases F
    Scand J Urol Nephrol; 2005; 39(3):194-9. PubMed ID: 16118089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats.
    Grases F; Sanchis P; Perello J; Isern B; Prieto RM; Fernandez-Palomeque C; Fiol M; Bonnin O; Torres JJ
    Front Biosci; 2006 Jan; 11():136-42. PubMed ID: 16146720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Potential Relationship Between Phytate Ingestion, Urinary Phytate Excretion, and Renal Stone Risk in a Unique Human Model: No Hard Evidence in Support of Phytate as a Stone Inhibitor.
    Fakier S; Rodgers A
    J Ren Nutr; 2020 Sep; 30(5):396-403. PubMed ID: 31928801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of potassium phytate effects on decreasing urinary calcium in rats.
    Grases F; Perelló J; Simonet BM; Prieto RM; García-Raja A
    Urol Int; 2004; 72(3):237-43. PubMed ID: 15084770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytate reduces age-related cardiovascular calcification.
    Grases F; Sanchis P; Perello J; Isern B; Prieto RM; Fernandez-Palomeque C; Saus C
    Front Biosci; 2008 May; 13():7115-22. PubMed ID: 18508720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors.
    Costa-Bauzá A; Barceló C; Perelló J; Grases F
    Int Urol Nephrol; 2002; 34(4):447-51. PubMed ID: 14577482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxalate and phytate of soy foods.
    Al-Wahsh IA; Horner HT; Palmer RG; Reddy MB; Massey LK
    J Agric Food Chem; 2005 Jul; 53(14):5670-4. PubMed ID: 15998131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phytate and osteopontin in the mechanism of soft tissue calcification.
    Grases F; Prieto RM; Sanchis P; Saus C; De Francisco T
    J Nephrol; 2008; 21(5):768-75. PubMed ID: 18949733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of post-ESWL residual lithiasis depending on the type of calculus and urine composition.
    Grases F; Costa-Bauzá A; Isern B; Sanchis P; Perelló J; Hierro F; Conte Visus A
    Arch Esp Urol; 2009 Jul; 62(6):473-82. PubMed ID: 19736377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An experimental study on residual lithiasis after shock wave lithotripsy.
    Costa-Bauzá A; Perelló J; Isern B; Grases F
    Urol Res; 2005 Feb; 33(1):51-6. PubMed ID: 15633055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats.
    Grases F; Sanchis P; Perelló J; Isern B; Prieto RM; Fernández-Palomeque C; Torres JJ
    Circ J; 2007 Jul; 71(7):1152-6. PubMed ID: 17587727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.